Index,NCTId,Condition,Change,Reference,Variable,Timepoint,Endpoint Art
0,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
1,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Vital Signs Measurements,3 Days,Primary Endpoint
2,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
3,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
4,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Not Mentioned,3 Days,Primary Endpoint
5,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,"Auc From Time 0 And Extrapolated To Infinite Time, Total Exposure(Aucinf)",48 Hours,Secondary Endpoint
6,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Auc From Time 0 To The Last Non-Zero Concentration(Auclast),48 Hours,Secondary Endpoint
7,NCT04984707,Androgenetic Alopecia,Maximum Observed Concentration (Cmax),Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
8,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
9,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Half Life（T½）,48 Hours,Secondary Endpoint
10,NCT04984707,Androgenetic Alopecia,"Apparent Total Systemic Clearance, Calculated As Dose/Aucinf(Cl/F)",Not Mentioned,Not Mentioned,48 Hours,Secondary Endpoint
11,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Apparent Volume Of Distribution(Vd/F),48 Hours,Secondary Endpoint
12,NCT04984707,Androgenetic Alopecia,Not Mentioned,Not Mentioned,Elimination Rate Constant（Kel）,48 Hours,Secondary Endpoint
13,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At Baseline.,Primary Endpoint
14,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,Immediately After Intervention.,Primary Endpoint
15,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 4 Weeks After Intervention.,Primary Endpoint
16,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 12 Weeks After Intervention.,Primary Endpoint
17,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Global Cognition,At 24 Weeks After Intervention.,Primary Endpoint
18,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At Baseline.,Primary Endpoint
19,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,Immediately After Intervention.,Primary Endpoint
20,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 4 Weeks After Intervention.,Primary Endpoint
21,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 12 Weeks After Intervention.,Primary Endpoint
22,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Memory,At 24 Weeks After Intervention.,Primary Endpoint
23,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At Baseline.,Primary Endpoint
24,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,Immediately After Intervention.,Primary Endpoint
25,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 4 Weeks After Intervention.,Primary Endpoint
26,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 12 Weeks After Intervention.,Primary Endpoint
27,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Attention,At 24 Weeks After Intervention.,Primary Endpoint
28,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At Baseline.,Primary Endpoint
29,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,Immediately After Intervention.,Primary Endpoint
30,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 4 Weeks After Intervention.,Primary Endpoint
31,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 12 Weeks After Intervention.,Primary Endpoint
32,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Visual/Spatial Function,At 24 Weeks After Intervention.,Primary Endpoint
33,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At Baseline.,Primary Endpoint
34,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,Immediately After Intervention.,Primary Endpoint
35,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 4 Weeks After Intervention.,Primary Endpoint
36,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 12 Weeks After Intervention.,Primary Endpoint
37,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Cognition-Executive Function,At 24 Weeks After Intervention.,Primary Endpoint
38,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Iadl,At Baseline.,Secondary Endpoint
39,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Iadl,Immediately After Intervention.,Secondary Endpoint
40,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Iadl,At 4 Weeks After Intervention.,Secondary Endpoint
41,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Iadl,At 12 Weeks After Intervention.,Secondary Endpoint
42,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Iadl,At 24 Weeks After Intervention.,Secondary Endpoint
43,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Senior Fitness Test (Sft),At Baseline.,Secondary Endpoint
44,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Senior Fitness Test (Sft),Immediately After Intervention.,Secondary Endpoint
45,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Senior Fitness Test (Sft),At 4 Weeks After Intervention.,Secondary Endpoint
46,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Senior Fitness Test (Sft),At 12 Weeks After Intervention.,Secondary Endpoint
47,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Senior Fitness Test (Sft),At 24 Weeks After Intervention.,Secondary Endpoint
48,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Unipedal Stance Test (Ust),At Baseline.,Secondary Endpoint
49,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Unipedal Stance Test (Ust),Immediately After Intervention.,Secondary Endpoint
50,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Unipedal Stance Test (Ust),At 4 Weeks After Intervention.,Secondary Endpoint
51,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Unipedal Stance Test (Ust),At 12 Weeks After Intervention.,Secondary Endpoint
52,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Physical Function-Unipedal Stance Test (Ust),At 24 Weeks After Intervention.,Secondary Endpoint
53,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Global Well-Being Scale (Gwbs),At Baseline.,Secondary Endpoint
54,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Global Well-Being Scale (Gwbs),Immediately After Intervention.,Secondary Endpoint
55,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Global Well-Being Scale (Gwbs),At 4 Weeks After Intervention.,Secondary Endpoint
56,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Global Well-Being Scale (Gwbs),At 12 Weeks After Intervention.,Secondary Endpoint
57,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Global Well-Being Scale (Gwbs),At 24 Weeks After Intervention.,Secondary Endpoint
58,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Interpersonal Relationship Scale (Irs),At Baseline.,Secondary Endpoint
59,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Interpersonal Relationship Scale (Irs),Immediately After Intervention.,Secondary Endpoint
60,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Interpersonal Relationship Scale (Irs),At 4 Weeks After Intervention.,Secondary Endpoint
61,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Interpersonal Relationship Scale (Irs),At 12 Weeks After Intervention.,Secondary Endpoint
62,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Interpersonal Relationship Scale (Irs),At 24 Weeks After Intervention.,Secondary Endpoint
63,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),At Baseline.,Secondary Endpoint
64,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),Immediately After Intervention.,Secondary Endpoint
65,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),At 4 Weeks After Intervention.,Secondary Endpoint
66,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),At 12 Weeks After Intervention.,Secondary Endpoint
67,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Psychosocial Factors-Geriatric Depression Scale-Short Form (Gds-Sf),At 24 Weeks After Intervention.,Secondary Endpoint
68,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At Baseline.,Secondary Endpoint
69,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,Immediately After Intervention.,Secondary Endpoint
70,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At 4 Weeks After Intervention.,Secondary Endpoint
71,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At 12 Weeks After Intervention.,Secondary Endpoint
72,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Utility,At 24 Weeks After Intervention.,Secondary Endpoint
73,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue Scale,At Baseline.,Secondary Endpoint
74,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue Scale,Immediately After Intervention.,Secondary Endpoint
75,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue Scale,At 4 Weeks After Intervention.,Secondary Endpoint
76,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue Scale,At 12 Weeks After Intervention.,Secondary Endpoint
77,NCT04984694,"Cognitive Dysfunction, Cognitive Change, Independent Living, Quality Of Life, Video Games",Not Mentioned,Not Mentioned,Quality Of Life-Eq5D-Visual Analogue Scale,At 24 Weeks After Intervention.,Secondary Endpoint
78,NCT04984564,Educational Problems,Not Mentioned,Not Mentioned,Feedback Of Individual Fellow In Training On Virtual And Simulator Based Learning,Survey Was Conducted From August To July 2020. Subjects Had Two Month Period To Respond.,Primary Endpoint
79,NCT04984564,Educational Problems,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
80,NCT04984135,"Coronary Stenosis, Drug-Coated Balloon",Not Mentioned,Not Mentioned,In-Segment Late Lumen Loss,6 Months,Primary Endpoint
81,NCT04984135,"Coronary Stenosis, Drug-Coated Balloon",Not Mentioned,Not Mentioned,Target Lesion Failure,6 Months,Secondary Endpoint
82,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
83,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Primary Endpoint
84,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Tnf Alfa,Baseline - 1 Week,Primary Endpoint
85,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Rank-L,Baseline - 1 Week,Primary Endpoint
86,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Opg,Baseline - 1 Week,Primary Endpoint
87,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
88,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Ppd,Baseline - 1 Week,Secondary Endpoint
89,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
90,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
91,NCT04983849,"Mmp8, Mmp9, Il1, Il6, Il8, Il17, Tnf Alfa, Rank-L, Opg, Cal, Ppd, Gi, Fmps, Fmbs",Not Mentioned,Not Mentioned,Not Mentioned,Baseline - 1 Week,Secondary Endpoint
92,NCT04983719,"Atypical, Myoma",Not Mentioned,Not Mentioned,Evaluation Of Video,Day 1,Primary Endpoint
93,NCT04983719,"Atypical, Myoma",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
94,NCT04983641,Orthopedic Disorder,Not Mentioned,Not Mentioned,"Pre-Visit Promis Completion Rates In Orthopaedic Patients Receiving Reminder E-Mails, Digital Patient Portal (""Mychart"") Message Reminders, Or No Messages Prior To Scheduled Clinic Visit",1 Week,Primary Endpoint
95,NCT04983641,Orthopedic Disorder,Not Mentioned,Not Mentioned,"At-Visit Promis Completion Rates In Orthopaedic Patients Receiving Reminder E-Mails, Digital Patient Portal (""Mychart"") Message Reminders, Or No Messages Prior To Scheduled Clinic Visit",1 Week,Primary Endpoint
96,NCT04983641,Orthopedic Disorder,Overall (Pre-Visit And,Not Mentioned,"Orthopaedic Patients Receiving Reminder E-Mails, Digital Patient Portal (""Mychart"") Message Reminders, Or No Messages Prior To Scheduled Clinic Visit",1 Week,Primary Endpoint
97,NCT04983641,Orthopedic Disorder,Not Mentioned,Not Mentioned,Not Mentioned,1 Week,Secondary Endpoint
98,NCT04983641,Orthopedic Disorder,Promis Form Completion Rates According To Patient Demographics,Not Mentioned,Not Mentioned,1 Week,Secondary Endpoint
99,NCT04983524,"Post-Operative Pain, Chronic, Necrotic Pulp",Not Mentioned,Not Mentioned,Post-Operative Pain,One Week. Line Of 10 Points,Primary Endpoint
100,NCT04983524,"Post-Operative Pain, Chronic, Necrotic Pulp",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
101,NCT04983459,"Prostatic Neoplasms, Recurrence",Not Mentioned,Not Mentioned,Rate Per Patient Of Pet-Psma For The Detection Of Biochemical Recurrence,12 Months,Primary Endpoint
102,NCT04983459,"Prostatic Neoplasms, Recurrence",Not Mentioned,Not Mentioned,Rate Per Region Of Psma-Pet For The Detection Of Biochemical Recurrence,12 Months,Secondary Endpoint
103,NCT04983381,"Pelvic Pain, Pelvic Floor; Relaxation",Not Mentioned,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
104,NCT04983381,"Pelvic Pain, Pelvic Floor; Relaxation",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
105,NCT04983212,Peri-Implantitis,Prevalence Of Peri-Implantitis,Not Mentioned,Not Mentioned,01/01/2015 - 01/01/2020,Primary Endpoint
106,NCT04983212,Peri-Implantitis,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
107,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Circulating Endothelial Progenitor Cells Concentration And Microparticles Derived From Endothelial Cells,"Data Collected After 4 Weeks, 8 Weeks And 12 Weeks.",Primary Endpoint
108,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Not Mentioned,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
109,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Level Of Micro Inflammation,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
110,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Level Of Endothelial Dysfunction,"After Patient Visit (0 Weeks, 4, 8 And 12 Weeks)",Secondary Endpoint
111,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Blood Pressure,"Each Visit (0 Weeks, 4 Weeks, 8 Weeks And 12 Weeks) For 24 Hours",Secondary Endpoint
112,NCT04983160,Chronic Kidney Disease,Not Mentioned,Not Mentioned,Glomerular Filtration Ratio,"After Patient Visit (0 Weeks, 4 Weeks, 8 Weeks And 12 Weeks)",Secondary Endpoint
113,NCT04983160,Chronic Kidney Disease,Microalbuminuria / Proteinuria,Not Mentioned,Not Mentioned,"Daily, Using First Urine Of The Day As A Sample.",Secondary Endpoint
114,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
115,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
116,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
117,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
118,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
119,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
120,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
121,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
122,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Weighing Machine,Up To 12 Weeks,Primary Endpoint
123,NCT04983147,Obesity,Body Mass Index Calculation,Not Mentioned,Not Mentioned,Up To 12 Weeks,Primary Endpoint
124,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
125,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
126,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
127,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
128,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
129,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
130,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
131,NCT04983147,Obesity,Not Mentioned,Not Mentioned,Weighing Machine,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
132,NCT04983147,Obesity,Body Mass Index Calculation,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 1 Year",Secondary Endpoint
133,NCT04983056,Fournier Gangrene,Number Of Patients,Not Mentioned,Not Mentioned,Six Months,Primary Endpoint
134,NCT04983056,Fournier Gangrene,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
135,NCT04982978,Vaping Related Disorder,Not Mentioned,Not Mentioned,Effect Of Threat Appraisal On Vaping Intention,6-Weeks,Primary Endpoint
136,NCT04982978,Vaping Related Disorder,Not Mentioned,Not Mentioned,Effect Of Perceived Vulnerability On Intention,6-Weeks,Secondary Endpoint
137,NCT04982978,Vaping Related Disorder,Not Mentioned,Not Mentioned,Effect Of Perceived Severity On Intention,6-Weeks,Secondary Endpoint
138,NCT04982874,Drug Use,Not Mentioned,Geometric Mean Ratio,Not Mentioned,1 Month,Primary Endpoint
139,NCT04982874,Drug Use,Not Mentioned,Not Mentioned,Not Mentioned,90%,Primary Endpoint
140,NCT04982874,Drug Use,Not Mentioned,Not Mentioned,Pharmacokinetics Parameter,1 Month,Secondary Endpoint
141,NCT04982874,Drug Use,Not Mentioned,Not Mentioned,Pharmacokinetics Parameter,1 Month,Secondary Endpoint
142,NCT04982861,Drug Use,Not Mentioned,Geometric Mean Ratio,Not Mentioned,3 Months,Primary Endpoint
143,NCT04982861,Drug Use,Not Mentioned,Not Mentioned,Not Mentioned,90%,Primary Endpoint
144,NCT04982861,Drug Use,Not Mentioned,Not Mentioned,Pharmacokinetics Parameter,3 Months,Secondary Endpoint
145,NCT04982861,Drug Use,Not Mentioned,Not Mentioned,Pharmacokinetics Parameter,3 Months,Secondary Endpoint
146,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
147,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Fev1,3 Months,Secondary Endpoint
148,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
149,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
150,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
151,NCT04982809,Interstitial Lung Disease,Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
152,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Not Mentioned,6 Weeks,Primary Endpoint
153,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Neck Pain And Disability Scale (Npds),Not Mentioned,Not Mentioned,6 Weeks,Primary Endpoint
154,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Neck And Jaw Range Of Motion (Rom),Not Mentioned,Not Mentioned,6 Weeks,Primary Endpoint
155,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
156,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
157,NCT04982601,"Temporomandibular Disorders, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint Pain, Range Of Motion, Yoga, Quality Of Life",Not Mentioned,Not Mentioned,Not Mentioned,6 Weeks,Secondary Endpoint
158,NCT04982523,Post Traumatic Stress Disorder,Change Of Post-Traumatic Stress Symptoms,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Primary Endpoint
159,NCT04982523,Post Traumatic Stress Disorder,Change Of Depression,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
160,NCT04982523,Post Traumatic Stress Disorder,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
161,NCT04982523,Post Traumatic Stress Disorder,Not Mentioned,Not Mentioned,College To Adaptation,"Baseline, 4 Weeks, 8Weeks",Secondary Endpoint
162,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,Not Mentioned,Reading Speed Day 0,Day 0,Primary Endpoint
163,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,Not Mentioned,Reading Speed M3,Month 3,Primary Endpoint
164,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,Not Mentioned,Visual Acuity Using The Etdrs Chart Day 0,Day 0,Secondary Endpoint
165,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,Not Mentioned,Visual Acuity Using The Etdrs Chartm3,Month 3,Secondary Endpoint
166,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,Not Mentioned,Maculare Thickness Day0,Day 0,Secondary Endpoint
167,NCT04982484,"Ophthalmopathy, Wet Macular Degeneration",Not Mentioned,Not Mentioned,Maculare Thickness M3,Month 3,Secondary Endpoint
168,NCT04982341,Hypoxemic Respiratory Failure,Number Of Patients,Not Mentioned,Not Mentioned,"Through Study Completion, An Average Of 28 Days",Primary Endpoint
169,NCT04982341,Hypoxemic Respiratory Failure,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
170,NCT04982263,Covid19,Correlation Of Disease Severity With Results Of Laboratory Test,Not Mentioned,Not Mentioned,Baseline Results Of Coagulation Profile And Baseline Disease Severity Assessment,Primary Endpoint
171,NCT04982263,Covid19,Agreement Of Abnormalities In Coagulation Profile,Not Mentioned,Measured Inflammatory Markers,Baseline Measurement Of Inflammatory Markers,Secondary Endpoint
172,NCT04982159,Invasive Fusariosis,Not Mentioned,Not Mentioned,Clinical Evolution,6 Weeks After Diagnosis,Primary Endpoint
173,NCT04982159,Invasive Fusariosis,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
174,NCT04982055,Critical Illness,Peak Anti-Xa Activity,Not Mentioned,Not Mentioned,Peak Anti-Xa Activity Obtained 4 Hours After Start Of Low Molecular Weight Heparin Administration,Primary Endpoint
175,NCT04982055,Critical Illness,Trough Anti-Xa Activity,Not Mentioned,Not Mentioned,Trough Anti-Xa Activity Measured 24 Hours After Start Of Low Molecular Weight Administration,Secondary Endpoint
176,NCT04982055,Critical Illness,Auc (0-24H),Not Mentioned,Not Mentioned,0-24 Hours,Secondary Endpoint
177,NCT04981652,"Dairy Products, Muscle Protein Synthesis, Aging, Physical Activity",Not Mentioned,Not Mentioned,Not Mentioned,"Assessed At Baseline (Day 0-3), Intervention Diet (4-7) And Intervention Diet + Activity (Day 8-10)",Primary Endpoint
178,NCT04981652,"Dairy Products, Muscle Protein Synthesis, Aging, Physical Activity",Not Mentioned,Not Mentioned,Not Mentioned,"Assessed At Baseline (Day 0-3), Intervention Diet (4-7) And Intervention Diet + Activity (Day 8-10)",Secondary Endpoint
179,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Treatment Emergent Adverse Events,28 Days,Primary Endpoint
180,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Not Mentioned,24 Hours,Secondary Endpoint
181,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Not Mentioned,24 Hours,Secondary Endpoint
182,NCT04981561,Major Depressive Disorder,Not Mentioned,Not Mentioned,Not Mentioned,72 Hours,Secondary Endpoint
183,NCT04981483,Placenta Accreta,Not Mentioned,Not Mentioned,Not Mentioned,Intraoperative,Primary Endpoint
184,NCT04981483,Placenta Accreta,Number Of Units Of Packed,Not Mentioned,Not Mentioned,Till 48 Hours Postpartum,Secondary Endpoint
185,NCT04981483,Placenta Accreta,Not Mentioned,Not Mentioned,Not Mentioned,Intraoperative And 48 Hours Postpartum,Secondary Endpoint
186,NCT04981483,Placenta Accreta,Not Mentioned,Not Mentioned,Not Mentioned,Till 6 Weeks Postpartum,Secondary Endpoint
187,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Worsening Of Clinical Findings,During The Study,Primary Endpoint
188,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Complete Resolution Of Symptoms And Signs,Fifth Day After Examination,Secondary Endpoint
189,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Complete Resolution Of Symptoms And Signs,Tenth Day After Examination,Secondary Endpoint
190,NCT04981379,Covid19,Negative Rt-Pcr Test For Sars-Cov-2,Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
191,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,Tenth Day After Examination,Secondary Endpoint
192,NCT04981379,Covid19,Negative Rt-Pcr Test For Sars-Cov-2,Not Mentioned,Not Mentioned,Thirtieth Day After Examination,Secondary Endpoint
193,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,Thirtieth Day After Examination,Secondary Endpoint
194,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Development Of Signs Of Pneumonia,During The Study,Secondary Endpoint
195,NCT04981379,Covid19,Requirement Of Respiratory Support With Oxygen Mask,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
196,NCT04981379,Covid19,Requirement Of Respiratory Support With High Flow Oxygen,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
197,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Mechanical Ventilation,During The Study,Secondary Endpoint
198,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
199,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Not Mentioned,During The Study,Secondary Endpoint
200,NCT04981379,Covid19,Not Mentioned,Not Mentioned,Initiation Of Study Drugs,During The Study,Secondary Endpoint
201,NCT04981249,"Covid-19, Chronic Disease",Not Mentioned,Not Mentioned,Covid-19 Severe Infection,From 27-February-2020 To 15-June-2020,Primary Endpoint
202,NCT04981249,"Covid-19, Chronic Disease",Not Mentioned,Not Mentioned,Covid-19 Mortality,From 27-February-2020 To 15-June-2020,Primary Endpoint
203,NCT04981249,"Covid-19, Chronic Disease",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
204,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Primary Endpoint
205,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Primary Endpoint
206,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
207,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Not Mentioned,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
208,NCT04981197,Heart Failure,Not Mentioned,Not Mentioned,Changes In Heart Rate Variability,"Baseline, 4 Week, 8 Week, 12 Week",Secondary Endpoint
209,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Tampa Kinesiophobia Index,First Measurement Two Weeks After Surgery (Intervetion 58.2; Control 54.1),Primary Endpoint
210,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 89.3; Control 88.1),Primary Endpoint
211,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,First Measurement Two Weeks After Surgery (Intervetion 21.6; Control 22.1),Primary Endpoint
212,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Tampa Kinesiophobia Index,Second Measurement Six Weeks After Surgery (Intervetion 36.9; Control 42.9),Secondary Endpoint
213,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 29; Control 70.5),Secondary Endpoint
214,NCT04981106,Exercise,Not Mentioned,Not Mentioned,Not Mentioned,Second Measurement Six Weeks After Surgery (Intervetion 6.9; Control 13.2),Secondary Endpoint
215,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Not Mentioned,Not Mentioned,Detrusor Underactivity,February 2005 And December 2020,Primary Endpoint
216,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Not Mentioned,Not Mentioned,Bladder Outlet Obstruction,February 2005 And December 2020,Primary Endpoint
217,NCT04981080,"Detrusor Underactivity, Bladder Outlet Obstruction",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
218,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Not Mentioned,Not Mentioned,Bladder Oversensitivity,November 2010 And October 2020,Primary Endpoint
219,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Not Mentioned,Not Mentioned,Detrusor Overactivity,November 2010 And October 2020,Primary Endpoint
220,NCT04981054,"Bladder Oversensitivity, Detrusor, Overactive",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
221,NCT04981015,Bladder Oversensitivity,Parameters,Correlation,Not Mentioned,July 2009 To December 2020,Primary Endpoint
222,NCT04981015,Bladder Oversensitivity,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
223,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Not Mentioned,At 12 Months During Follow-Up Of Early Breast Cancer,Primary Endpoint
224,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Quality Of Life During Follow-Up Modality,"At Baseline, 6 Months And 12 Months",Secondary Endpoint
225,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Patient Satisfaction,At 6 Months And 12 Months,Secondary Endpoint
226,NCT04980989,"Breast Cancer, Early-Onset",Not Mentioned,Not Mentioned,Symptoms,"At Baseline, 6 Months And 12 Months",Secondary Endpoint
227,NCT04980989,"Breast Cancer, Early-Onset",Use Of Other Healthcare Services,Not Mentioned,Not Mentioned,At 6 Months And 12 Months,Secondary Endpoint
228,NCT04980937,"Traumatic Injury, Peroneal Nerve Injury, Sport Injury",Not Mentioned,Not Mentioned,Successful Nerve Reconstruction,1 Year,Primary Endpoint
229,NCT04980937,"Traumatic Injury, Peroneal Nerve Injury, Sport Injury",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
230,NCT04980729,Pelvic Tumor,Compare The Change Of Acetabular Rotation Center Before And After Surgery,Not Mentioned,Template-Guided Group,"""Through Study Completion, An Average Of 2 Years""",Primary Endpoint
231,NCT04980729,Pelvic Tumor,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
232,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Cheeks Appearance,Not Mentioned,Not Mentioned,Immediately After The Evaluation,Primary Endpoint
233,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Not Mentioned,Not Mentioned,Thickness Evaluation Of Specific Orofacial Muscles,Immediately After The Evaluation,Secondary Endpoint
234,NCT04980586,"Obstructive Sleep Apnea, Breathing, Sleep-Disordered, Muscle Weakness, Muscle Disorder, Face, Swallowing Disorder",Not Mentioned,Not Mentioned,Not Mentioned,Immediately After The Evaluation,Secondary Endpoint
235,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Corpus Cavernosum Electromyography Amplitudes And Frequency,Not Mentioned,Not Mentioned,1 Hour,Primary Endpoint
236,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Corpus Cavernosum Electromyography Relaxation Degree,Not Mentioned,Not Mentioned,1 Hour,Primary Endpoint
237,NCT04980508,"Erectile Dysfunction Due To Diseases Classified Elsewhere, Covid19",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
238,NCT04980274,Critically Ill Patients,Improvement In Sofa Score After 48 Hours Of Icu Stay,Not Mentioned,Not Mentioned,48 Hours,Primary Endpoint
239,NCT04980274,Critically Ill Patients,Not Mentioned,Not Mentioned,Not Mentioned,28 Day,Secondary Endpoint
240,NCT04980274,Critically Ill Patients,Not Mentioned,Not Mentioned,Not Mentioned,28 Days,Secondary Endpoint
241,NCT04980274,Critically Ill Patients,Not Mentioned,Not Mentioned,Not Mentioned,28 Days,Secondary Endpoint
242,NCT04980209,Femoroacetabular Impingement,Not Mentioned,Not Mentioned,Vas Scale,1 Year After Operation,Primary Endpoint
243,NCT04980209,Femoroacetabular Impingement,Not Mentioned,Not Mentioned,Mhhs Scale,1 Year After Operation,Primary Endpoint
244,NCT04980209,Femoroacetabular Impingement,Not Mentioned,Not Mentioned,Not Mentioned,1 Day After Operation,Primary Endpoint
245,NCT04980209,Femoroacetabular Impingement,Not Mentioned,Not Mentioned,Not Mentioned,1 Day After Operation,Primary Endpoint
246,NCT04980209,Femoroacetabular Impingement,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
247,NCT04980196,Urogenital Prolapse,Not Mentioned,Not Mentioned,Urological Outcome Following Surgery In Women With Pelvic Organ Prolapse And Urinary Tract Dysfunction,3Months,Primary Endpoint
248,NCT04980196,Urogenital Prolapse,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
249,NCT04980131,Vertebral Fracture,Not Mentioned,Not Mentioned,"First Puncture Success Rate,Number Of Insertions Before Reaching The Desired Position, Number Of Fluoroscopy Before Reaching The Desired Position, Radiation Dosage Before Reaching The Desired Position, Operation Time Before Reaching The Desired Position",Twenty Months,Primary Endpoint
250,NCT04980131,Vertebral Fracture,Not Mentioned,Not Mentioned,Vas Scores After Surgery,Twenty-Two Months,Primary Endpoint
251,NCT04980131,Vertebral Fracture,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
252,NCT04980118,"Breast Cancer, Body Weight Changes, Weight Loss, Nutrition Related Cancer",To Evaluate A Nutritional Intervention For Women Newly Diagnosed With Breast Cancer 9 Weight Control,Not Mentioned,Not Mentioned,Six Months,Primary Endpoint
253,NCT04980118,"Breast Cancer, Body Weight Changes, Weight Loss, Nutrition Related Cancer",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
254,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Adverse Events (Saes),From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
255,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
256,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
257,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,From First Dose Of Study Drug Up To 30 Days Post Last Dose Of Study Drug (Up To 79.77 Weeks),Primary Endpoint
258,NCT04980040,Type 2 Diabetes Mellitus,Haemoglobin (Hba1C) Levels,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
259,NCT04980040,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Fasting Blood Glucose Levels,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
260,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Not Mentioned,"Baseline (Before Administration Of Alogliptin), 13 Weeks (±2 Weeks) And 26 Weeks (±2 Weeks) After Administration",Secondary Endpoint
261,NCT04980040,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Final Effectiveness Assessment,Up To Week 26,Secondary Endpoint
262,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants With Serious Adverse Events (Saes) And Serious Adverse Drug Reactions (Sadrs),Not Mentioned,Not Mentioned,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
263,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Unexpected Adverse Events (Aes) And Adverse Drug Reactions (Adrs) Not Mentioned In Precautions,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
264,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Already Known Adrs,Week 13,Primary Endpoint
265,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Already Known Adrs,Week 26,Primary Endpoint
266,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Already Known Adrs,Week 39,Primary Endpoint
267,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Already Known Adrs,Week 52,Primary Endpoint
268,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Already Known Adrs,Week 153,Primary Endpoint
269,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Non-Serious Adrs,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
270,NCT04980014,Type 2 Diabetes Mellitus,Percentage Of Participants,Not Mentioned,Abnormal Laboratory Findings Reported As Aes,First Dose Of Surveillance Drug Treatment To Within 30 Days After The End Of The Treatment (Up To 153 Weeks),Primary Endpoint
271,NCT04980014,Type 2 Diabetes Mellitus,Change,"Haemoglobin A1C (Hba1C) Levels, Baseline","Haemoglobin A1C (Hba1C) Levels, Baseline","Baseline, Weeks 13 And 26",Secondary Endpoint
272,NCT04980014,Type 2 Diabetes Mellitus,Change,"Fasting Serum Glucose, Baseline","Fasting Serum Glucose, Baseline","Baseline, Weeks 13 And 26",Secondary Endpoint
273,NCT04980014,Type 2 Diabetes Mellitus,Change,"Total Cholesterol, Baseline","Total Cholesterol, Baseline","Baseline, Weeks 13 And 26",Secondary Endpoint
274,NCT04980014,Type 2 Diabetes Mellitus,Change,"Low Density Lipoprotein-Cholesterol (Ldl-C), Baseline","Low Density Lipoprotein-Cholesterol (Ldl-C), Baseline","Baseline, Weeks 13 And 26",Secondary Endpoint
275,NCT04980014,Type 2 Diabetes Mellitus,Change,"Baseline, High Density Lipoprotein-Cholesterol (Hdl-C)","Baseline, High Density Lipoprotein-Cholesterol (Hdl-C)","Baseline, Weeks 13 And 26",Secondary Endpoint
276,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
277,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
278,NCT04980014,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,"Baseline, Weeks 13 And 26",Secondary Endpoint
279,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Not Mentioned,Not Mentioned,"Operative Difficulties As Conversion, Operative Time, Biliary Injury",At The Time Of Cholecysctomy,Primary Endpoint
280,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Postoperative Complications,Not Mentioned,Not Mentioned,30 Days After The Operation,Primary Endpoint
281,NCT04979936,"Acute Cholecystitis, Empyema, Gallbladder",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
282,NCT04979689,Erbs Palsy,Not Mentioned,Not Mentioned,Modified Mallet Scale,12Th Weeks,Primary Endpoint
283,NCT04979689,Erbs Palsy,Not Mentioned,Not Mentioned,Not Mentioned,"12Th Weeks, 5Th Day",Secondary Endpoint
284,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
285,NCT04979481,Mental Health Wellness 1,Resilience,Not Mentioned,Not Mentioned,Up To 8 Months,Primary Endpoint
286,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Positive Coping,Up To 8 Months,Primary Endpoint
287,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Self-Esteem,Up To 8 Months,Primary Endpoint
288,NCT04979481,Mental Health Wellness 1,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
289,NCT04979364,"Chronic Pain, Opioid Misuse",Psychometric Properties Of Pomi Scale,Not Mentioned,Not Mentioned,Once. At Inclusion (Test Phase),Primary Endpoint
290,NCT04979364,"Chronic Pain, Opioid Misuse",Psychometric Properties Of Pomi Scale,Not Mentioned,Not Mentioned,Once. At 2 To 4 Weeks (Re-Test Phase),Primary Endpoint
291,NCT04979364,"Chronic Pain, Opioid Misuse",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
292,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Not Mentioned,Not Mentioned,Not Mentioned,At Inclusion In The Cohort During The Acute Episode,Primary Endpoint
293,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Not Mentioned,Not Mentioned,Not Mentioned,At Inclusion In The Cohort During The Acute Episode,Primary Endpoint
294,NCT04979208,"Coronavirus Disease 2019, Stroke, Acute Myocardial Infarction",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
295,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Not Mentioned,Not Mentioned,Patient Survival,30 Days,Primary Endpoint
296,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Not Mentioned,Not Mentioned,Kidney Survival,30 Days,Primary Endpoint
297,NCT04979195,Covid-19 Positive Patients With Acute Kidney Injury,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
298,NCT04979091,"Covid19, Critical Illness",Not Mentioned,Not Mentioned,Sex Hormone In Critical Ill Covid-19 Patients,Day At Admission,Primary Endpoint
299,NCT04979091,"Covid19, Critical Illness",Not Mentioned,Not Mentioned,Sex Hormone In Critical Ill Patients,Day At Admission,Primary Endpoint
300,NCT04979091,"Covid19, Critical Illness",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
301,NCT04979026,Deep Venous Thrombosis,Change Of Peak Flow Velocity,Not Mentioned,Not Mentioned,"The Peak Flow Velocity Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
302,NCT04979026,Deep Venous Thrombosis,Change Of Flow Volume,Not Mentioned,Not Mentioned,"The Flow Volume Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
303,NCT04979026,Deep Venous Thrombosis,Number Of Participants,Not Mentioned,Not Mentioned,"Stasis Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
304,NCT04979026,Deep Venous Thrombosis,Number Of Participants,Not Mentioned,Not Mentioned,"Deep Venous Thrombosis Was Determined On The 1St, 3Rd, And 14Th Days After Surgery.",Primary Endpoint
305,NCT04979026,Deep Venous Thrombosis,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
306,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Primary Endpoint
307,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,7 Days,Secondary Endpoint
308,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Additional Aa Metabolites,14 Days,Secondary Endpoint
309,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,"Urine, Nicotine Equivalents And Cema","Urine, Nicotine Equivalents And Cema",14 Days,Secondary Endpoint
310,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,"Urine, Tsnas","Urine, Tsnas",14 Days,Secondary Endpoint
311,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
312,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,"Cotinine, Nicotine",14 Days,Secondary Endpoint
313,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
314,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
315,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
316,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
317,NCT04979013,"Smoking, Smoking Cessation, Tobacco Use",Not Mentioned,Not Mentioned,Not Mentioned,14 Days,Secondary Endpoint
318,NCT04978974,"Chronic Conditions, Multiple",Not Mentioned,Not Mentioned,Using Perceived Stress Scale,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
319,NCT04978974,"Chronic Conditions, Multiple",Not Mentioned,Not Mentioned,Health-Related Quality Of Life,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
320,NCT04978974,"Chronic Conditions, Multiple",Not Mentioned,Not Mentioned,Using Coping Strategies Questionnaire,10Th Session (One Month And One Week From First Assessment),Primary Endpoint
321,NCT04978974,"Chronic Conditions, Multiple",Not Mentioned,Baseline,Not Mentioned,Base Line Were Used In 5Th (Two Weeks And 3 Days) And 10Th Session (One Month And One Week From First Assessment),Secondary Endpoint
322,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Self-Reported Physical Disability,Booster (12 Weeks From Baseline),Primary Endpoint
323,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Self-Reported Physical Disability,6-Month Follow-Up,Primary Endpoint
324,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Not Mentioned,6-Month Follow-Up,Primary Endpoint
325,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Chronic Pain Acceptance,Booster (12 Weeks From Baseline),Secondary Endpoint
326,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Chronic Pain Acceptance,6-Month Follow-Up,Secondary Endpoint
327,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Engagement In Valued Activities,Booster (12 Weeks From Baseline),Secondary Endpoint
328,NCT04978961,Chronic Pain,Not Mentioned,Not Mentioned,Engagement In Valued Activities,6-Month Follow-Up,Secondary Endpoint
329,NCT04978883,Sjogren'S Syndrome,Not Mentioned,Not Mentioned,"Observational Study, Data Analysis To Identify The Risk Factors Of Pss-Ild",6 Months From Baseline,Primary Endpoint
330,NCT04978883,Sjogren'S Syndrome,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
331,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,1. Week,Primary Endpoint
332,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,4. Week,Primary Endpoint
333,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,8. Week,Primary Endpoint
334,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,1.Week,Primary Endpoint
335,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,4.Week,Primary Endpoint
336,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,8.Week,Primary Endpoint
337,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,1.Week,Primary Endpoint
338,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,4.Week,Primary Endpoint
339,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Not Mentioned,8.Week,Primary Endpoint
340,NCT04978805,Cancer,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
341,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Not Mentioned,Not Mentioned,Urodynamic Stress Incontinence,November 2010 And October 2020,Primary Endpoint
342,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Not Mentioned,Not Mentioned,Detrusor Overactivity,November 2010 And October 2020,Primary Endpoint
343,NCT04978714,"Urodynamic Stress Incontinence, Detrusor Overactivity",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
344,NCT04978688,Healthy,"Pk: Area Under The Concentration-Time Curve From Time Zero To Hour 24 (Auc0-24) Of Relugolix, E2, Estrone (El), Ethinylestradiol (Ee), Neta",Not Mentioned,Not Mentioned,Predose And Up To 24 Hours At Weeks 3 And 6,Primary Endpoint
345,NCT04978688,Healthy,Not Mentioned,Not Mentioned,Not Mentioned,"Pk: Maximum Concentration (Cmax) Of Relugolix, E2, El, Neta",Primary Endpoint
346,NCT04978688,Healthy,Not Mentioned,Not Mentioned,Not Mentioned,"Pk: Time To Maximum Concentration (Tmax) Of Relugolix, E2, El, Ee, Neta",Primary Endpoint
347,NCT04978688,Healthy,Change,"Serum Follicle Stimulating Hormone (Fsh) At Week 6, Baseline","Serum Follicle Stimulating Hormone (Fsh) At Week 6, Baseline","Baseline, Week 6",Secondary Endpoint
348,NCT04978688,Healthy,Change,"Baseline, Serum Luteinizing Hormone (Lh) At Week 6","Baseline, Serum Luteinizing Hormone (Lh) At Week 6","Baseline, Week 6",Secondary Endpoint
349,NCT04978688,Healthy,Change,Baseline,Not Mentioned,"Baseline, Week 6",Secondary Endpoint
350,NCT04978688,Healthy,Change,"Baseline, Serum E2 And E1 At Week 6","Baseline, Serum E2 And E1 At Week 6","Baseline, Week 6",Secondary Endpoint
351,NCT04978688,Healthy,Change,"Telopepetide Concentrations At Week 6, Baseline","Telopepetide Concentrations At Week 6, Baseline","Baseline, Week 6",Secondary Endpoint
352,NCT04978688,Healthy,Not Mentioned,Not Mentioned,Not Mentioned,8 Weeks,Secondary Endpoint
353,NCT04978688,Healthy,Not Mentioned,Not Mentioned,Not Mentioned,8 Weeks,Secondary Endpoint
354,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",Not Mentioned,Not Mentioned,"Total Bacteria And E.Faecalis In 5 Different Samples (Sr1, S1, S2, Sr2 And S3) Taken From Teeth Were Measured Using The Ddpcr",Change From Baseline To Postoperative 7 Days,Primary Endpoint
355,NCT04978545,"Periapical Periodontitis, Polymerase Chain Reaction, Intracanal Medicament, Enterococcus Faecalis Infection",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
356,NCT04978532,"Procedural Pain, Pain, Acute",Change Of Pain From Before Venipuncture To After Venipuncture (Assessed By Children),Not Mentioned,Not Mentioned,Before Venipuncture Procedure And After Venipuncture Procedure (Immediately After The Injector Was Removed),Primary Endpoint
357,NCT04978532,"Procedural Pain, Pain, Acute",Change Of Pain From Before Venipuncture To After Venipuncture (Assessed By Parents,Not Mentioned,Not Mentioned,Before Venipuncture Procedure And After Venipuncture Procedure (Immediately After The Injector Was Removed),Primary Endpoint
358,NCT04978532,"Procedural Pain, Pain, Acute",Not Mentioned,Not Mentioned,Not Mentioned,"Before Venipuncture Procedure, During Venipuncture Procedure (When Needle Insertion And The First Blood Was Seen In Injector, Until Needle Removed), And After Venipuncture Procedure (Immediately After The Injector Was Removed)",Secondary Endpoint
359,NCT04978532,"Procedural Pain, Pain, Acute",Not Mentioned,Not Mentioned,Not Mentioned,"Before Venipuncture Procedure, During Venipuncture Procedure (When Needle Insertion And The First Blood Was Seen In Injector, Until Needle Removed), And After Venipuncture Procedure (Immediately After The Injector Was Removed)",Secondary Endpoint
360,NCT04978441,"Significant Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm",Not Mentioned,"Patients, Correlation, Baseline",Not Mentioned,"Through Study Completion, An Average Of 1 Year",Primary Endpoint
361,NCT04978441,"Significant Correlation Between Baseline Personality Characteristics, Changing Emotions Throughout The Day, And Glycemic Levels In Patients With T1Dm",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
362,NCT04978402,"Interchromosomal Breakpoint, Infertility",Not Mentioned,Not Mentioned,Reproductive Risk,Day 1,Primary Endpoint
363,NCT04978402,"Interchromosomal Breakpoint, Infertility",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
364,NCT04978233,Covid-19,Change In The Acceptability Of The Opal App For Covid-19,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Primary Endpoint
365,NCT04978233,Covid-19,Change In The Usability Of The Opal App For Covid-19,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Primary Endpoint
366,NCT04978233,Covid-19,Contact With The Healthcare Team,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
367,NCT04978233,Covid-19,Change In Symptoms,Not Mentioned,Not Mentioned,From Day 1 To Day 14,Secondary Endpoint
368,NCT04978233,Covid-19,Not Mentioned,Not Mentioned,Patient Satisfaction With Scheduled Teleconsultations,From Day 1 To Day 14,Secondary Endpoint
369,NCT04978233,Covid-19,Change,Not Mentioned,Vital Signs Temperature,From Day 1 To Day 14,Secondary Endpoint
370,NCT04978233,Covid-19,Change,Not Mentioned,Vital Signs Respiration Rate,From Day 1 To Day 14,Secondary Endpoint
371,NCT04978233,Covid-19,Change,Not Mentioned,Vital Signs Oxygen Saturation,From Day 1 To Day 14,Secondary Endpoint
372,NCT04978233,Covid-19,Change,Not Mentioned,Vital Signs Heart Rate,From Day 1 To Day 14,Secondary Endpoint
373,NCT04978233,Covid-19,Change,Not Mentioned,Vital Signs Blood Pressure,From Day 1 To Day 14,Secondary Endpoint
374,NCT04978220,"Depression Unipolar, Insomnia",Not Mentioned,Not Mentioned,Not Mentioned,1 Year,Primary Endpoint
375,NCT04978220,"Depression Unipolar, Insomnia",Not Mentioned,Not Mentioned,Not Mentioned,1 Year,Secondary Endpoint
376,NCT04978155,Arterio-Venous Fistula,Not Mentioned,Not Mentioned,Not Mentioned,6 Weeks,Primary Endpoint
377,NCT04978155,Arterio-Venous Fistula,Not Mentioned,Not Mentioned,"Finally Placed, The Rate Of Planning Change Between The Surgical Project",During The Surgery,Secondary Endpoint
378,NCT04978155,Arterio-Venous Fistula,Not Mentioned,Not Mentioned,Not Mentioned,12 Months,Secondary Endpoint
379,NCT04977921,Educational Problems,Not Mentioned,Not Mentioned,Improve Student'S Performance Per Clinical Lab Session,13 Lab Session-13 Weeks,Primary Endpoint
380,NCT04977921,Educational Problems,Not Mentioned,Not Mentioned,Evaluate Effectiveness Of Teaching Pedagogy,Week 14,Primary Endpoint
381,NCT04977921,Educational Problems,Not Mentioned,Not Mentioned,Assess Students' Perception Of Usability And Learning Of Elsevier Clinical Skill:,Up To 15 Weeks,Secondary Endpoint
382,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Reduce Labor Pain,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
383,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Postpartum Comfort Levels,2 Hours After Birth,Primary Endpoint
384,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",A Maternal Information Form,Not Mentioned,Not Mentioned,Before Birth,Primary Endpoint
385,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Not Mentioned,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
386,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Not Mentioned,2 Hours After Birth,Primary Endpoint
387,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Evalution Labour Pain,Evaluation Was Done Until Delivery (On Average Between 8-12 Hours),Primary Endpoint
388,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Evalution Postpartum Comfort,2 Hours After Birth,Primary Endpoint
389,NCT04977713,"Labor Pain, Hydrotherapy, Acupressure, Postpartum Period",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
390,NCT04977687,"Machine Learning, Acute Kidney Injury, Renal Replacement Therapy, Prediction Models",Not Mentioned,"Patients, Required Renal Replacement Therapy","Patients, Required Renal Replacement Therapy",14 Days,Primary Endpoint
391,NCT04977687,"Machine Learning, Acute Kidney Injury, Renal Replacement Therapy, Prediction Models",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
392,NCT04977661,Nonalcoholic Steatohepatitis (Nash),Not Mentioned,Not Mentioned,Not Mentioned,3 Months,Primary Endpoint
393,NCT04977661,Nonalcoholic Steatohepatitis (Nash),Normalization Of Hepatic Aminotransferases(Alt And Ast),Not Mentioned,Not Mentioned,3 Months,Secondary Endpoint
394,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Tumor Size,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
395,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Tumor Location,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
396,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Number Of Lesions,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
397,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Margin,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
398,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Tumor Texture,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
399,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Pancreatic Tail Contraction,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
400,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Complicated Pancreatitis,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
401,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Pancreatic Duct/Bile Duct Dilatation,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
402,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Extrapancreatic Tissue Invasion,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
403,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Not Mentioned,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
404,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Lymphatic Metastasis,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
405,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Ct Value Of Pancreas Plain Scan,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
406,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Ct Value Of Lesion Plain Scan,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
407,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Ct Value Of Pancreas Artery Phase,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
408,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Ct Value Of Lesion Artery Phase,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
409,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Ct Value Of Pancreas Portal Phase,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
410,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Ct Value Of Lesion Portal Phase,Preoperative Contrast-Enhanced Ct Performed Within 2 Months Before Surgery Or Biopsy,Primary Endpoint
411,NCT04977596,"Neuroendocrine Tumor Of Pancreas, Carcinoma, Pancreatic, Ct",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
412,NCT04977557,Dry Beriberi,Change In Overall Neuropathy Limitation Scale (Onls) Score,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Primary Endpoint
413,NCT04977557,Dry Beriberi,Change In Leg Swelling,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
414,NCT04977557,Dry Beriberi,Change In Muscle Power,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
415,NCT04977557,Dry Beriberi,Change In Muscle Cramp,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
416,NCT04977557,Dry Beriberi,Change In Deep Tendon Reflexes,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
417,NCT04977557,Dry Beriberi,Change In Squat Test,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
418,NCT04977557,Dry Beriberi,Change In Pain Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
419,NCT04977557,Dry Beriberi,Change,Not Mentioned,Sensation,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
420,NCT04977557,Dry Beriberi,Change In Vibration Sensation,Not Mentioned,Not Mentioned,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
421,NCT04977557,Dry Beriberi,Change,Not Mentioned,Touch Sensation,"Before Treatment With Thiamine (Baseline ) And After 1 Week, 6Week, 12 Week Of Treatment",Secondary Endpoint
422,NCT04977518,Infective Endocarditis,"Complications (Neurological Events, Systemic Embolism, And Congestive Heart Failure) Of Infective Endocarditis",Not Mentioned,Not Mentioned,"During The Hospitalization, Average Of 1 Months",Primary Endpoint
423,NCT04977518,Infective Endocarditis,Not Mentioned,Not Mentioned,Not Mentioned,"During The Hospitalization, Average Of 1 Months",Primary Endpoint
424,NCT04977518,Infective Endocarditis,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
425,NCT04977505,Shoulder Dislocation,Hounsfield Unit Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Primary Endpoint
426,NCT04977505,Shoulder Dislocation,Hounsfield Unit Of Ossification Site,Not Mentioned,Not Mentioned,2 Years After Surgery,Primary Endpoint
427,NCT04977505,Shoulder Dislocation,Unossified Area Of Anchor Tunnel,Not Mentioned,Not Mentioned,2 Years After Surgery,Secondary Endpoint
428,NCT04977505,Shoulder Dislocation,Not Mentioned,Not Mentioned,Ossification Quality Score,2 Years After Surgery,Secondary Endpoint
429,NCT04977440,Intensive Care Unit Syndrome,Not Mentioned,Not Mentioned,Effect Of High Protein Intake On Glycemic Control,Up To 7 Days,Primary Endpoint
430,NCT04977440,Intensive Care Unit Syndrome,Not Mentioned,Not Mentioned,Effect Of High Protein Intake On Serum Electrolytes,Up To 7 Days,Primary Endpoint
431,NCT04977440,Intensive Care Unit Syndrome,Not Mentioned,Not Mentioned,Effect Of High Protein Intake On Icu Outcome,Up To 7 Days,Secondary Endpoint
432,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Primary Endpoint
433,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
434,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Not Mentioned,Up To 55 Days,Secondary Endpoint
435,NCT04977219,Stroke,Not Mentioned,Not Mentioned,Discharge Destination,Up To 55 Days,Secondary Endpoint
436,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Not Mentioned,Not Mentioned,Not Mentioned,3Day,Primary Endpoint
437,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Not Mentioned,Not Mentioned,Not Mentioned,3 Day,Secondary Endpoint
438,NCT04977011,"Diabetic Ketoacidosis, Heart Disease, Ischemic, Stroke, Gastrointestinal Bleeding, Acute Kidney Injury, Heart Failure, Trauma, Septic Shock, Respiratory Failure, Pneumonia, Intracerebral Hemorrhage, Head Injury, Liver Diseases",Not Mentioned,Not Mentioned,Richards-Campbell Sleep Scale,3 Day,Secondary Endpoint
439,NCT04976673,"Lichen Planus, Oral",Not Mentioned,Not Mentioned,Size Of Oral Lichen Planus,12 Weeks,Primary Endpoint
440,NCT04976673,"Lichen Planus, Oral",Not Mentioned,Not Mentioned,Pain Rating,12 Weeks,Secondary Endpoint
441,NCT04976543,"Cirrhosis, Portal Vein Thrombosis, Esophageal Varices",Not Mentioned,Not Mentioned,Rebleeding,6-Week,Primary Endpoint
442,NCT04976543,"Cirrhosis, Portal Vein Thrombosis, Esophageal Varices",Not Mentioned,Not Mentioned,Death,6-Week,Secondary Endpoint
443,NCT04976504,"Desaturation Of Blood, Anesthesia",Not Mentioned,Not Mentioned,Additional Warning Time Provided By Ori Trigger,"From Time Of Starting Preoxygenation Until The Time Of Spo2 90%, Assessed Up To 20 Minutes",Primary Endpoint
444,NCT04976504,"Desaturation Of Blood, Anesthesia",Not Mentioned,Correlation,Not Mentioned,"From Time Of Starting Preoxygenation Until The Time Of Spo2 90%, Assessed Up To 20 Minutes",Secondary Endpoint
445,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,Not Mentioned,Not Mentioned,January 2017 - June 2021,Primary Endpoint
446,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,Not Mentioned,Description Of Tumor Nature,January 2017 - June 2021,Primary Endpoint
447,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,Not Mentioned,Not Mentioned,January 2017 - June 2021,Primary Endpoint
448,NCT04976439,"Colorectal Cancer, Apc Gene Mutation, Tp53 Gene Mutation, Pik3Ca Gene Mutation, Kras Mutation-Related Tumors, Mlh1 Gene Mutation",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
449,NCT04976361,Prp,Measurement Of Vessel Density,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
450,NCT04976361,Prp,Measurement Of Retinal Thickness,Not Mentioned,Not Mentioned,6 Months,Primary Endpoint
451,NCT04976361,Prp,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
452,NCT04976114,Anxiety,Not Mentioned,Not Mentioned,Anxiety Level,"Presurgery, Just The Moment Before To Surgery",Primary Endpoint
453,NCT04976114,Anxiety,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
454,NCT04976088,"Trauma Injury, Inflammation",Hours (Day 4) After Treatment Start,Not Mentioned,"Left Extreme Means ""No Pain = 0"" While The Right Extreme Means ""Worst Pain Imaginable = 100"") For Pain At Rest, Change From Baseline",72 Hours,Primary Endpoint
455,NCT04976088,"Trauma Injury, Inflammation",Area Under The Curve (Auc) For Pain,Not Mentioned,Spid0-4D And Spid0-8D),Day 4 And Day 8,Secondary Endpoint
456,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"Time-Points (Including Patients' Home Measurements), From Day 1 To Day 8, Change From Baseline Of Vas (Visual Analogue Scale 0-100 Mm, Where ""No Pain = 0"" And ""Worst Pain Imaginable = 100"") For Pain At Rest","Day 1, Day 2, Day 3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
457,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"Measured Through Vas Scale (Visual Analogue Scale 0-100 Mm, Where ""No Pain = 0"" And ""Worst Pain Imaginable = 100"") During From Baseline To Day 8",From Day 1 Until The Date Of Resolution Of Pain At Rest (Maximum Day 8),Secondary Endpoint
458,NCT04976088,"Trauma Injury, Inflammation",Hours (Day 8) After Treatment Start,Not Mentioned,Change From Baseline,Day 4 And Day 8,Secondary Endpoint
459,NCT04976088,"Trauma Injury, Inflammation",Hours (Day 4) After Treatment Start,Not Mentioned,Not Mentioned,Day 4,Secondary Endpoint
460,NCT04976088,"Trauma Injury, Inflammation",Medication (Paracetamol),Baseline,Not Mentioned,From Baseline To Day 8,Secondary Endpoint
461,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,"Amount Of Tablets Of Rescue Medication Consumed From Baseline To Day 8, Using A Patient Diary",Not Mentioned,From Baseline To Day 8,Secondary Endpoint
462,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"Imp Adhesion, Performed Daily By Patients And At Day 4 And Day 8 By The Open Staff Member; Following 5-Point Ordinal Scale: 0:≥90% Adhered; 1:≥75% To <90% Adhered; 2:≥50% To <75% Adhered; 3:<50% Adhered But Not Detached; 4:Plaster Detached","Day 1, Day 2, Day 3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
463,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
464,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,Blood Pressure Measured In Mmhg,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
465,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,Blood Pressure Measured In Mmhg,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
466,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,Rate Measured In Bpm,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
467,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,Number Of Patient Withdrawals,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
468,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,Not Mentioned,"Day 1, Day 2, Day3, Day 4, Day 5,Day 6, Day 7, Day 8",Secondary Endpoint
469,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,Spreading Beyond Test Site,"Day 1, Day 4 And Day 8",Secondary Endpoint
470,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,Severe,"Day 1, Day 4 And Day 8",Secondary Endpoint
471,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,Severe,"Day 1, Day 4 And Day 8",Secondary Endpoint
472,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,Severe,"Day 1, Day 4 And Day 8",Secondary Endpoint
473,NCT04976088,"Trauma Injury, Inflammation",Not Mentioned,Not Mentioned,"Global Assessment Of Local Tolerability At Imp Administration Site By Investigator And Patient According To The Following Score: 3=Excellent; 2=Good; 1=Fair; 0=Poor, Assessed At Day 4 And Day 8",Day 4 And Day 8,Secondary Endpoint
474,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Mean Change In Pain Score,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Primary Endpoint
475,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Mean Change In Inflammation (Cell And Flare) Scores,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Primary Endpoint
476,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Not Mentioned,Not Mentioned,Not Mentioned,Assessed For 1 Months After Drug Insertion,Secondary Endpoint
477,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Not Mentioned,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
478,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Proportion Of Eyes Requiring Additional Post-Operative Therapy,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
479,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Number Of Patient Call-Backs Regarding Post-Operative Pain,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
480,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Number Of Pharmacy Call-Backs Regarding Post-Operative Medication,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
481,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Not Mentioned,Not Mentioned,Adverse Events,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
482,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Mean Change In Iop,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
483,NCT04975971,"Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating Keratoplasty, Nuclear Cataract, Cortical Cataract, Cataract Senile",Change,Not Mentioned,Not Mentioned,Assessed For 3 Months After Drug Insertion,Secondary Endpoint
484,NCT04975659,Communication,Pain Score,Not Mentioned,Not Mentioned,"Throughout Study Completion, Average Of 10 Months",Primary Endpoint
485,NCT04975659,Communication,Not Mentioned,Baseline,Not Mentioned,"Through Study Completion, Average Of 10 Months",Primary Endpoint
486,NCT04975659,Communication,Preoperative Anxiety Score,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Primary Endpoint
487,NCT04975659,Communication,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Secondary Endpoint
488,NCT04975659,Communication,Not Mentioned,Not Mentioned,Not Mentioned,"Through Study Completion, Average Of 10 Months",Secondary Endpoint
489,NCT04975542,Respiratory Function Impaired,Change In Chest Wall Excursion,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Chest Wall Excursion Within 5 Minutes Of Treatment Completion.,Primary Endpoint
490,NCT04975542,Respiratory Function Impaired,Change,Not Mentioned,Forced Vital Capacity (Fvc),Measure Assessing A Change From Baseline Fvc Value Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
491,NCT04975542,Respiratory Function Impaired,Fev1),Not Mentioned,Forced Expiratory Volume,Measure Assessing A Change From Baseline In Forced Expiratory Volume At 1 Second Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
492,NCT04975542,Respiratory Function Impaired,Change,Not Mentioned,Fev1,Measure Assessing A Change From Baseline Fev1/Fvc Ratio Value Via Pulmonary Function Testing Within 5 Minutes Of Treatment Completion.,Primary Endpoint
493,NCT04975542,Respiratory Function Impaired,Change,Not Mentioned,Respiratory Rate,Measure Assessing A Change From Baseline Respiratory Rate Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
494,NCT04975542,Respiratory Function Impaired,Change In Heart Rate,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Heart Rate Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
495,NCT04975542,Respiratory Function Impaired,Not Mentioned,Not Mentioned,Not Mentioned,Measure Assessing A Change From Baseline Oxygen Saturation Within 5 Minutes Of Treatment Completion.,Secondary Endpoint
496,NCT04975529,"Exercise, Diet",Mean Change From Baseline,Not Mentioned,Youth Self-Reported Physical Activity Using The Patient-Reported Outcomes Measurement Information System (Promis) Measure,6-,Primary Endpoint
497,NCT04975529,"Exercise, Diet",Mean Change From Baseline,Not Mentioned,Youth Self-Reported Self-Efficacy For Physical Activity Using The Validated Physical Activity Self-Efficacy Scale,6-,Secondary Endpoint
498,NCT04975529,"Exercise, Diet",Mean Change From Baseline,Not Mentioned,Youth Self-Reported Dietary Intake Assessed Using The National Cancer Institute (Nci) Fruit And Vegetable Screener,6-,Secondary Endpoint
499,NCT04975529,"Exercise, Diet",Mean Change From Baseline,Not Mentioned,Youth Self-Confidence Assessed Using The Positive Youth Development (Pyd) Short Form Confidence Scale,6-,Secondary Endpoint
500,NCT04975412,Acne Vulgaris,Not Mentioned,Not Mentioned,Acne Severity,Initial Consult,Primary Endpoint
501,NCT04975412,Acne Vulgaris,Not Mentioned,Not Mentioned,Whole Blood Zinc Level,Initial Consult,Primary Endpoint
502,NCT04975412,Acne Vulgaris,Not Mentioned,Not Mentioned,Demographics,Initial Consult,Secondary Endpoint
503,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,At 07:00 Hours After Caffeine And Placebo Administration,Primary Endpoint
504,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Recording Of Nocturnal Sleep,Between 03:00-07:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
505,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,Between 07:15-08:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
506,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Not Mentioned,Between 07:00-08:15 Hours After Caffeine And Placebo Administration,Secondary Endpoint
507,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Psychomotor Vigilance Task,Between 07:15-07:30 Hours After Caffeine And Placebo Administration,Secondary Endpoint
508,NCT04975360,"Sleep Inertia, Caffeine, Placebo",N-Back Task,Not Mentioned,Not Mentioned,Between 07:30-07:40 Hours After Caffeine And Placebo Administration,Secondary Endpoint
509,NCT04975360,"Sleep Inertia, Caffeine, Placebo",D2 Attention Task,Not Mentioned,Not Mentioned,Between 07:40-07:45 Hours After Caffeine And Placebo Administration,Secondary Endpoint
510,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Cortisol Awakening Response,Between 07:00-08:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
511,NCT04975360,"Sleep Inertia, Caffeine, Placebo",Not Mentioned,Not Mentioned,Recording Of Morning Nap Opportunity,Between 08:00-09:00 Hours After Caffeine And Placebo Administration,Secondary Endpoint
512,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Fitting,24 Months,Primary Endpoint
513,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Positioning,24 Months,Primary Endpoint
514,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Proximal Contact,24 Months,Primary Endpoint
515,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Marginal Adaptation,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
516,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
517,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Gingival Status,24 Months,Primary Endpoint
518,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
519,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
520,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Secondary Caries,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
521,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,History Of Trauma,24 Months,Primary Endpoint
522,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Clinical Pulp Pathology,24 Months,Primary Endpoint
523,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
524,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Not Mentioned,24 Months,Primary Endpoint
525,NCT04975321,"Primary Dental Caries, Multisurface Origin (Diagnosis)",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
526,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Not Mentioned,Not Mentioned,Not Mentioned,"From Transition To Breastfeeding, Up To 1 Week.",Primary Endpoint
527,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Not Mentioned,Not Mentioned,Not Mentioned,"From Admission To Discharge, Up To 4 Weeks",Primary Endpoint
528,NCT04975282,"Preterm, Feeding, Bottle, Feeding Behavior, Feeding, Breast",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
529,NCT04975126,Cataract,Not Mentioned,Not Mentioned,Decisional Conflict Scale Score,Day Of Pre-Assessment Visit (1 Week Before Surgery),Primary Endpoint
530,NCT04975126,Cataract,Not Mentioned,Not Mentioned,Decision Regret Scale Score,1 Month After Surgery,Primary Endpoint
531,NCT04975126,Cataract,Number Of Correctly,Not Mentioned,Not Mentioned,Day Of Pre-Assessment Visit (1 Week Before Surgery),Primary Endpoint
532,NCT04975126,Cataract,Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
533,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Change From Visual Analogue Pain Scale Score,Not Mentioned,Not Mentioned,"Before And After Treatment (12 Sessions, 6Th. And 12Th. Weeks)]",Primary Endpoint
534,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Change From Isokinetic Muscle Strength Of The Hamstring And Quadriceps Femoris Muscles,Not Mentioned,Not Mentioned,"Before And After Treatment (12 Sessions, 6Th. And 12Th. Weeks)]",Primary Endpoint
535,NCT04975113,"Patellofemoral Pain Syndrome, Kinesiotape, Exercise, Strength",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
536,NCT04975048,"Healthy, Gen1 Gene Mutation",Not Mentioned,Not Mentioned,Changes In Serum Lipids,"Week 0, Week 4, Week 8, Week 16",Primary Endpoint
537,NCT04975048,"Healthy, Gen1 Gene Mutation",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
538,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Primary Endpoint
539,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Auc 0-8 H,"Pre-Dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Primary Endpoint
540,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,"Aucgir,0-8 H","Pre-Dose, 0-8 Hours",Primary Endpoint
541,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Not Mentioned,"Pre-Dose, 0-8 Hours",Primary Endpoint
542,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Tmax,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300,330,360,420,480 Minutes；",Secondary Endpoint
543,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Auc 0-2 H,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120 Minutes",Secondary Endpoint
544,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Half-Life (T1/2) Of Serum Insulin,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Secondary Endpoint
545,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Insulin From Time Zero To 4 H,"Pre-Dose, 5,10,20,30,40,50,60,75,90,105,120,150,180,210,240 Minutes",Secondary Endpoint
546,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Insulin From Time Zero To Infinite Time,"Pre-Dose, 5,10,20,30,45,10,20,30,40,50,60,75,90,105,120,150,180,210,240,270,300, 330,360,420,480 Minutes；",Secondary Endpoint
547,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Aucgir，0-2 H,"Pre-Dose, 0-2 Hours",Secondary Endpoint
548,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Aucgir，0-4 H,"Pre-Dose, 0-4 Hours",Secondary Endpoint
549,NCT04975022,"Pk, Pd, And Safety",Not Mentioned,Not Mentioned,Tgirmax,"Pre-Dose, 0-8 Hours",Secondary Endpoint
550,NCT04974983,"Glioblastoma, Angiogenesis",Not Mentioned,Not Mentioned,Functional Outcome,15 Months,Primary Endpoint
551,NCT04974983,"Glioblastoma, Angiogenesis",Not Mentioned,Not Mentioned,Nan,Nan,Secondary Endpoint
